Linvoseltamab Continues to Elicit Durable Efficacy in High-Risk Relapsed/Refractory Multiple Myeloma

Hans Lee, MD, discusses updated data from the LINKER-MM1 study in heavily pretreated relapsed/refractory multiple myeloma.

Related Keywords

United States ,Houston ,Texas ,American ,Hans Lee ,Department Of Lymphoma Myeloma ,American Society Of Hematology ,University Of Texas Md Anderson Cancer Center ,Myeloma Clinical Research ,Regeneron Pharmaceuticals Inc ,Multiple Myeloma Clinical Research ,Cancer Center ,Linvoseltamab ,Regn5458 ,Multiple Myeloma ,Myeloma ,D ,Phase 1 2 Linker Mm1 Study ,2023 Ash Annual Meeting ,Regeneron ,The University Of Texas Md Anderson Cancer Center ,